Founded in 2009 and having raised $192M, Ellume was focused on producing digital diagnostic products during the H1N1 outbreak. Ellume secured a $300M contract to supply newly developed SARS-COV-2 kits to the US in 2019. In 2021, the product was recalled due to false positive results. Ellume went bankrupt in 2023 and owed $140M to investors, partners, contractors and staff.
